

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the study design of the ASC4FIRST trial?**
 - a. A single-arm Phase I study evaluating asciminib as third-line therapy for relapsed/refractory chronic myeloid leukemia (CML) previously treated with ponatinib
 - b. A randomized Phase II study evaluating asciminib versus investigator-selected tyrosine kinase inhibitors (TKIs) as second-line therapy for relapsed/refractory CML previously treated with imatinib
 - c. A randomized Phase III study evaluating asciminib versus investigator-selected TKIs as first-line therapy for newly diagnosed CML**
- 2. Which statement best characterizes the major efficacy findings of the ASC4FIRST study?**
 - a. Inferior major molecular response (MMR) rate at week 48 with asciminib versus all investigator-selected TKIs
 - b. A numerical but nonsignificant improvement in MMR rate at week 48 with asciminib versus all investigator-selected TKIs
 - c. A significant improvement in MMR rate at week 48 with asciminib versus all investigator-selected TKIs**
- 3. Which of the following best describes the mechanism of action of olverembatinib?**
 - a. Second-generation BCR::ABL1 TKI
 - b. Third-generation BCR::ABL1 TKI**
 - c. Fourth-generation BCR::ABL1 TKI
- 4. The Phase III ASCEMBL trial evaluating asciminib versus bosutinib for chronic phase CML after at least 2 prior TKIs reported what efficacy finding at week 156?**
 - a. Inferior percentage of patients achieving BCR::ABL1^{IS} $\leq 1\%$ with asciminib versus bosutinib
 - b. No difference in percentage of patients achieving BCR::ABL1^{IS} $\leq 1\%$ with asciminib versus bosutinib
 - c. A significant improvement in percentage of patients achieving BCR::ABL1^{IS} $\leq 1\%$ with asciminib versus bosutinib**
- 5. What is the most commonly reported any-grade adverse event with nilotinib in the ENESTnd trial evaluating nilotinib versus imatinib for newly diagnosed CML?**
 - a. Muscle spasms
 - b. Rash**
 - c. Alopecia
 - d. Vomiting